EUVIMEDEUVIMED entdecken
Systematische ÜbersichtFallberichtÜbersichtsarbeit

Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review

Camille Braun, Kelly Grzywacz, Dorothée Dal Soglio, Eric Drouin, Marie E Chartier, Martha Dirks, Laurence Chapuy, Kathryn Samaan, François Graham, Louis Paradis, Anne Des Roches, Philippe Bégin

Journal of Investigational Allergology and Clinical Immunology · 14.04.2026 · 36 (2) · 100-112

DOI: 10.18176/jiaci.1098 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, online erschienen am 15.04.2026. Verfasst von Camille Braun und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Eosinophilia, Enteritis, Gastritis. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab has proven effective in the treatment of eosinophilic esophagitis (EoE) in randomized controlled trials. Its efficacy in other, less common and generally more severe eosinophilic gastrointestinal disorders (EGIDs) is scientifically plausible, although it has not been studied to date. Our objective was to describe published and our experience on the empirical use of dupilumab in patients affected by EGIDs with extraesophageal involvement. We retrospectively analyzed the medical charts of children diagnosed with extraesophageal EGIDs treated with dupilumab at our tertiary medical center. The Medline, Embase, and Cochrane databases were searched up to January 2025 for articles describing the use of dupilumab in patients with diagnosed or suspected extraesophageal EGID. Our cohort included 8 patients with a clinical and histological diagnosis of EGID and extraesophageal involvement. All of them had recurrent gastrointestinal symptoms refractory to standard treatments. Three patients had growth retardation. In all patients, symptoms and macroscopic and histological abnormalities, including eosinophilic infiltration, quickly improved after initiation of dupilumab. The systematic review identified 11 case reports (n=29 patients) of pediatric and adult patients with extraesophageal EGIDs treated with dupilumab. All 11 reports described significant clinical and histological improvement following therapy. Clinical experience suggests that dupilumab is effective in treating pediatric EGIDs with extraesophageal features. Given the rarity and high morbidity of these disorders, dupilumab could be considered a reasonable option while waiting for high-quality evidence from ongoing randomized controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEosinophiliaEnteritisGastritisHumansChildMaleFemaleChild, PreschoolRetrospective StudiesAdolescentTreatment Outcome

Stichwörter der Autor:innen

DupilumabEosinophilic colitisEosinophilic duodenitisEosinophilic enterocolitisEosinophilic gastritisEosinophilic gastrointestinal disordersPediatrics

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
  • Department of Pediatrics, Pulmonology, Allergy, Cystic Fibrosis, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.
  • Centre International de Recherche en Infectiologie, INSERM U1111, CNRS UMR 5308, Université Lyon 1, ENS de Lyon, Lyon, France.
  • Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
  • Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
  • Department of Medicine, Section of Allergy and Clinical Immunology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Zitieren

APA

Braun, C., Grzywacz, K., Dal Soglio, D., Drouin, E., Chartier, M. E., Dirks, M., Chapuy, L., Samaan, K., Graham, F., Paradis, L., Des Roches, A., & Bégin, P. (2026). Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review. Journal of Investigational Allergology and Clinical Immunology, 36(2), 100-112. https://doi.org/10.18176/jiaci.1098

Vancouver

Braun C, Grzywacz K, Dal Soglio D, Drouin E, Chartier ME, Dirks M, et al. Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review. Journal of Investigational Allergology and Clinical Immunology. 2026;36(2):100-112. doi:10.18176/jiaci.1098

BibTeX
@article{Braun2026,
  author = {Braun, Camille and Grzywacz, Kelly and Dal Soglio, Dorothée and Drouin, Eric and Chartier, Marie E and Dirks, Martha and Chapuy, Laurence and Samaan, Kathryn and Graham, François and Paradis, Louis and Des Roches, Anne and Bégin, Philippe},
  title = {Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review},
  journal = {Journal of Investigational Allergology and Clinical Immunology},
  year = {2026},
  volume = {36},
  number = {2},
  pages = {100--112},
  doi = {10.18176/jiaci.1098}
}
Kostenlos starten →